HEPATITIS C VIRUS INHIBITOR USEFUL FOR PREVENTION AND TREATMENT OF HEPATITIS C VIRUS INFECTION

PURPOSE: A novel hepatitis C virus inhibitor is provided which is useful for the prevention and treatment of hepatitis C virus infection. Also, provided are a preparation method thereof and a composition for the prevention and treatment of hepatitis C virus containing the same. CONSTITUTION: The hep...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, YONG JU, KANG, SEUNG WAN, SUNG, I TAEK, CHO, YEONG GYU, CHOI, SEONG PIL, LIM, JAE HONG, SONG, HO YEONG, KIM, WON SEOP, KIM, JONG YEOP, KIM, CHANG MYEONG, YOON, JU YONG, PARK, JI HYEON, SONG, JEONG UK
Format Patent
LanguageEnglish
Korean
Published 20.12.2004
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
Abstract PURPOSE: A novel hepatitis C virus inhibitor is provided which is useful for the prevention and treatment of hepatitis C virus infection. Also, provided are a preparation method thereof and a composition for the prevention and treatment of hepatitis C virus containing the same. CONSTITUTION: The hepatitis C virus inhibitor represented by the formula(1), or pharmaceutically acceptable salts, hydrates, solvates and tautomers thereof are provided, wherein X is O or S; R1 is hydrogen, alkyl which is optionally substituted with 1 to 3 substituents selected from halogen, alkoxy, alkoxycarbonyl, hydroxy, carboxy and aryl, alkoxy, alkoxycarbonyl optionally substituted with aryl, or aryl; R2 and R3 are independently hydrogen, alkyl which is optionally substituted with 1 to 3 substituents selected from halogen, hydroxy, alkoxy, alkylsulfonyl and aralkyloxy, alkoxycarbonyl, alkylsulfonylalkyl, aryl or heteroaryl; R5 is alkyl optionally substituted amino, alkylamino which is optionally substituted with alkylcarbonylamino, alkylcarbonyloxy or dialkylamino; alkoxy which is optionally substituted with 1 to 3 substituents selected from benzoyloxy, alkoxycarbonyl, alkyl, alkylsulfonyl, alkylcarbonylthio, alkoxycarbonylamino, and alkyl and oxo, and is optionally substituted with 1 to 3 substituents of heterocycle containing a double bond, aryl optionally substituted carboxy, or aralkyl optionally substituted with alkylcarbonyloxy; R6 is alkyl; R4 is alkyl which is optionally substituted with 1 to 3 substituents selected from alkoxy optionally substituted with heteroaryl, carboxy, alkylthio, alkoxycarbonyl, alkylaminocarbonyl, biphenyl, aryl, aryloxy, aralkyloxy, alkylaryl, amino optionally substituted with alkyl or alkylaryl, cycloalkyl, cycloalkyloxy, alkylaryl sulfonyl, heteroaryl optionally substituted with halogen and heteroarylthio, alkenyl which is optionally substituted with 1 to 3 substituents selected from halogen, aryl and heteroaryl, alkynyl which is optionally substituted with 1 to 3 substituents selected from alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, aryl and heteroaryl, -(CH2)N-cycloalkyl, -(CH2)N-cycloalkenyl, -(CH2)N-aryl, -(CH2)N-heterocycle or -(CH2)N-heteroaryl in which N is an integer of 1 to 10 and -CH2- group is optionally substituted with halogen when N is not 0.
AbstractList PURPOSE: A novel hepatitis C virus inhibitor is provided which is useful for the prevention and treatment of hepatitis C virus infection. Also, provided are a preparation method thereof and a composition for the prevention and treatment of hepatitis C virus containing the same. CONSTITUTION: The hepatitis C virus inhibitor represented by the formula(1), or pharmaceutically acceptable salts, hydrates, solvates and tautomers thereof are provided, wherein X is O or S; R1 is hydrogen, alkyl which is optionally substituted with 1 to 3 substituents selected from halogen, alkoxy, alkoxycarbonyl, hydroxy, carboxy and aryl, alkoxy, alkoxycarbonyl optionally substituted with aryl, or aryl; R2 and R3 are independently hydrogen, alkyl which is optionally substituted with 1 to 3 substituents selected from halogen, hydroxy, alkoxy, alkylsulfonyl and aralkyloxy, alkoxycarbonyl, alkylsulfonylalkyl, aryl or heteroaryl; R5 is alkyl optionally substituted amino, alkylamino which is optionally substituted with alkylcarbonylamino, alkylcarbonyloxy or dialkylamino; alkoxy which is optionally substituted with 1 to 3 substituents selected from benzoyloxy, alkoxycarbonyl, alkyl, alkylsulfonyl, alkylcarbonylthio, alkoxycarbonylamino, and alkyl and oxo, and is optionally substituted with 1 to 3 substituents of heterocycle containing a double bond, aryl optionally substituted carboxy, or aralkyl optionally substituted with alkylcarbonyloxy; R6 is alkyl; R4 is alkyl which is optionally substituted with 1 to 3 substituents selected from alkoxy optionally substituted with heteroaryl, carboxy, alkylthio, alkoxycarbonyl, alkylaminocarbonyl, biphenyl, aryl, aryloxy, aralkyloxy, alkylaryl, amino optionally substituted with alkyl or alkylaryl, cycloalkyl, cycloalkyloxy, alkylaryl sulfonyl, heteroaryl optionally substituted with halogen and heteroarylthio, alkenyl which is optionally substituted with 1 to 3 substituents selected from halogen, aryl and heteroaryl, alkynyl which is optionally substituted with 1 to 3 substituents selected from alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, aryl and heteroaryl, -(CH2)N-cycloalkyl, -(CH2)N-cycloalkenyl, -(CH2)N-aryl, -(CH2)N-heterocycle or -(CH2)N-heteroaryl in which N is an integer of 1 to 10 and -CH2- group is optionally substituted with halogen when N is not 0.
Author SONG, JEONG UK
LIM, JAE HONG
SUNG, I TAEK
KIM, CHANG MYEONG
KIM, JONG YEOP
CHO, YEONG GYU
PARK, JI HYEON
KANG, SEUNG WAN
CHOI, SEONG PIL
KIM, WON SEOP
SONG, HO YEONG
YOON, JU YONG
KIM, YONG JU
Author_xml – fullname: KIM, YONG JU
– fullname: KANG, SEUNG WAN
– fullname: SUNG, I TAEK
– fullname: CHO, YEONG GYU
– fullname: CHOI, SEONG PIL
– fullname: LIM, JAE HONG
– fullname: SONG, HO YEONG
– fullname: KIM, WON SEOP
– fullname: KIM, JONG YEOP
– fullname: KIM, CHANG MYEONG
– fullname: YOON, JU YONG
– fullname: PARK, JI HYEON
– fullname: SONG, JEONG UK
BookMark eNrjYmDJy89L5WSI83ANcAzxDPEMVnBWCPMMCg1W8PTz8HTyDPEPUggNdnUL9VFwAzIDglzDXP1CPP39FBz9XBRCglwdQ3yBAgr-bgrYjHBzdQYp5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8d5BRgYGJgaGBubGZuaOxsSpAgBUkDWx
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
Edition 7
ExternalDocumentID KR20040107367A
GroupedDBID EVB
ID FETCH-epo_espacenet_KR20040107367A3
IEDL.DBID EVB
IngestDate Fri Jul 19 15:04:24 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
Korean
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_KR20040107367A3
Notes Application Number: KR20040040967
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041220&DB=EPODOC&CC=KR&NR=20040107367A
ParticipantIDs epo_espacenet_KR20040107367A
PublicationCentury 2000
PublicationDate 20041220
PublicationDateYYYYMMDD 2004-12-20
PublicationDate_xml – month: 12
  year: 2004
  text: 20041220
  day: 20
PublicationDecade 2000
PublicationYear 2004
RelatedCompanies LG LIFE SCIENCES LTD
RelatedCompanies_xml – name: LG LIFE SCIENCES LTD
Score 2.592015
Snippet PURPOSE: A novel hepatitis C virus inhibitor is provided which is useful for the prevention and treatment of hepatitis C virus infection. Also, provided are a...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title HEPATITIS C VIRUS INHIBITOR USEFUL FOR PREVENTION AND TREATMENT OF HEPATITIS C VIRUS INFECTION
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20041220&DB=EPODOC&locale=&CC=KR&NR=20040107367A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFPVNp-LHlIDSt2I_s-1hSNemtM61o0vHnhztmoEo23AV_32TsOoeZG8hB0dycLn87nK_ADzkrDDmmj5T7XZHUy2WZ2quZ7k6w3qBseDMwqJReBDhILWeJ_akBh9VL4zkCf2W5Ijco2bc30t5Xq_-kliefFu5fszf-NTyyaddT6nQsaUbhqZ4vS4Zxl7sKq7b7SdKlEgZhx4tE7ecPdgXF2nBtE_GPdGXstoOKv4JHAy5vkV5CrX3ZQOO3OrvtQYcDjYlbz7ceN_6DF4DMnRoSMMRctE4TNIRCqMg7IU0TlA6In76gjioQ9yqYxKJ3BNyIg_RhDhUcPaj2Ef_qfCJfElyDvc-oW6g8oVOf-0y7SfbuzIvoL5YLtglIKxlc3ueiaIXtnRWtDtMIKeC2aYlCrdX0Nyl6Xq3-AaOK7ZDQ2tCvfz8Yrc8Mpf5nTToD-UXiTw
link.rule.ids 230,309,786,891,25594,76904
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_mFOebTsWPqQGlb8W2a7PtYUjXpjRua0eXjj052rUDUTZxFf99k7DqHmRvIQdHcnA5fvfxC8BDmmfGQtPnqtXuaKqZp4ma6kmqzrGeYSw4s7AYFB4G2I_N56k1rcB7OQsjeUK_JTki96g59_dCvtcff0ksV_ZWrh_TV761evJY11VKdGzqhqEpbq9LRqEbOorjdPuREkRSxqFHq4lb9h7stzgoFEz7ZNITcykf20HFO4aDEde3LE6g8raqQ80p_16rw-FwU_Lmy433rU_hxScjm1FGx8hBExrFY0QDn_YoCyMUj4kXDxAHdYhbdUICkXtCduAiFhGbCc5-FHroPxUekZ0kZ3DvEeb4Kj_o7Ncus360favmOVSXq2V-AQhrycJaJKLohU09z9qdXCCnLLeapijcXkJjl6ar3eI7qPlsOJgNaNC_hqOS-dDQGlAtPr_yGx6li_RWGvcHdsyMJw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=HEPATITIS+C+VIRUS+INHIBITOR+USEFUL+FOR+PREVENTION+AND+TREATMENT+OF+HEPATITIS+C+VIRUS+INFECTION&rft.inventor=KIM%2C+YONG+JU&rft.inventor=KANG%2C+SEUNG+WAN&rft.inventor=SUNG%2C+I+TAEK&rft.inventor=CHO%2C+YEONG+GYU&rft.inventor=CHOI%2C+SEONG+PIL&rft.inventor=LIM%2C+JAE+HONG&rft.inventor=SONG%2C+HO+YEONG&rft.inventor=KIM%2C+WON+SEOP&rft.inventor=KIM%2C+JONG+YEOP&rft.inventor=KIM%2C+CHANG+MYEONG&rft.inventor=YOON%2C+JU+YONG&rft.inventor=PARK%2C+JI+HYEON&rft.inventor=SONG%2C+JEONG+UK&rft.date=2004-12-20&rft.externalDBID=A&rft.externalDocID=KR20040107367A